DelveInsight’s ‘Cytomegalovirus Infection Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Cytomegalovirus Infection therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cytomegalovirus Infection pipeline domain.
For Cytomegalovirus Infection emerging drugs, the Cytomegalovirus Infection pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Cytomegalovirus Infection Pipeline Report
- DelveInsight’s Cytomegalovirus Infection Pipeline analysis depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Cytomegalovirus Infection treatment.
- The leading Cytomegalovirus Infection companies include Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others are evaluating their lead assets to improve the Cytomegalovirus Infection treatment landscape.
- Key Cytomegalovirus Infection pipeline therapies in various stages of development include mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, BT097, V 160, Brincidofovir, VBI-1501A, Adimlecleucel, Cytomegalovirus vaccine, Research programme: antibody therapeutics, LTV 20, and others.
- In June 2023, the FDA approved letermovir for the prevention of CMV illness in adult kidney transplant recipients at high risk (donor CMV-seropositive/recipient CMV-seronegative [D+/R-]). Letermovir is a first-in-class non-nucleoside that suppresses viral replication by targeting the viral terminase complex specifically.
Request a sample and discover the recent breakthroughs happening in the Cytomegalovirus Infection pipeline landscape @ Cytomegalovirus Infection Pipeline Outlook
Cytomegalovirus Infection Overview
Cytomegalovirus (CMV) is a common virus that can cause mild to severe end-organ dysfunction in immunocompromised patients with congenital CMV illness. Human cytomegalovirus (HCMV) is a member of the herpesviruses, Herpesviridae, or human herpesvirus-5 (HHV-5) viral family. Human CMV infections are frequently linked to the salivary glands. In healthy persons, CMV infection is asymptomatic, but in immunocompromised patients, it can be fatal.
Find out more about Cytomegalovirus Infection medication @ New Drug for Cytomegalovirus Infection
Cytomegalovirus Infection Treatment Analysis: Drug Profile
mRNA-1647: Moderna
mRNA-1647 is a vaccine that combines six mRNAs encoding two antigens to protect against CMV infection. Five of the six mRNAs encode CMV pentamer complex components, and one mRNA encodes the glycoprotein B (gB) protein, both of which are highly immunogenic. CMV entry into the majority of cells, including epithelial cells, is dependent on the pentamer complex, whereas gB is required for entry into all susceptible cells, including fibroblasts. A vaccination that induces an immune response against both pentamer and gB has the potential to prevent CMV entry into a variety of target cell types, hence preventing both primary and secondary infections.
Key Cytomegalovirus Infection Therapies and Companies
- mRNA-1647: Moderna
- CMV TCR T cell therapy: China Immunotech
- NPC-21: Nobelpharma
- HB-101: Hookipa Biotech GmbH
- Cytomegalovirus immune globulin: Biotest
- Posoleucel: AlloVir
- VBI-1501A: VBI Vaccines
- LTV 20: Lion TCR
Learn more about the novel and emerging Cytomegalovirus Infection pipeline therapies @ Cytomegalovirus Infection Clinical Trials
Cytomegalovirus Infection Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Intranasal
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Transdermal
- By Molecule Type
- Antisense oligonucleotide
- Gene therapy
- Hormones
- Neuropeptides
- Oligonucleotides
- Small Molecule
- Triglyceride
Scope of the Cytomegalovirus Infection Pipeline Report
-
- Coverage: Global
- Key Cytomegalovirus Infection Companies: Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others.
- Key Cytomegalovirus Infection Pipeline Therapies: mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, BT097, V 160, Brincidofovir, VBI-1501A, Adimlecleucel, Cytomegalovirus vaccine, Research programme: antibody therapeutics, LTV 20, and others.
Dive deep into rich insights for drugs used for Cytomegalovirus Infection treatment; visit @ Cytomegalovirus Infection Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Cytomegalovirus Infection Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Cytomegalovirus Infection Pipeline Therapeutics |
| 6. | Cytomegalovirus Infection Pipeline: Late Stage Products (Phase III) |
| 7. | Cytomegalovirus Infection Pipeline: Late Stage Products (Phase III) |
| 8. | Cytomegalovirus Infection Pipeline: Mid-Stage Products (Phase II) |
| 9. | Cytomegalovirus Infection Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Cytomegalovirus Infection therapy in the pipeline, reach out @ Cytomegalovirus Infection Medication
Related Reports
Cytomegalovirus Infection Epidemiology Forecast
Cytomegalovirus Infection Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Cytomegalovirus Infection epidemiology trends.
Cytomegalovirus Infection Market
Cytomegalovirus Infection Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic Cytomegalovirus Infection companies, including AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, among others.
Respiratory Syncytial Virus Market
Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key RSV companies, including Bavarian Nordic, Pfizer, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Swedish Orphan Biovitrum AB (SOBI), among others.
Acute Respiratory Distress Syndrome Market
Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute respiratory distress syndrome companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, among others.
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic obstructive pulmonary disease companies, including AstraZeneca, GlaxoSmithKline, Theravance, Inc, Innoviva, Chiesi Farmaceutici, among others.
Other Trending Reports
Image Guided Surgery Devices Market | Alopecia Market | Chronic Myelogenous Leukemia Market | Neuroblastoma Market | Alzheimer Disease Market | Osteoarthritis Market | Apheresis Market | Scleroderma Market | Hyperhidrosis Market | Opioid Induced Constipation Market | Cervical Intraepithelial Neoplasia Market | Automated External Defibrillators Market | Choroidal Neovascularization Market | Familial Primary Pulmonary Hypertension Market | Meningioma Market | Progressive Multifocal Leukoencephalopathy Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187